Trials / Completed
CompletedNCT06351748
Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 34,238 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to describe the real-world use and impact of semaglutide once-weekly (OW) among participants with type 2 diabetes mellitus (T2DM) in China. Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List \[NRDL\] in China\] and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023) will be included in this study. The study period will be 36 months prior to the first date of participants identification period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide | Participants received semaglutide OW according to local label and to routine clinical practice at the discretion of the treating physician. |
Timeline
- Start date
- 2024-01-02
- Primary completion
- 2024-03-29
- Completion
- 2024-03-29
- First posted
- 2024-04-08
- Last updated
- 2025-04-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06351748. Inclusion in this directory is not an endorsement.